Risedronate sodium

Risedronate sodium

Products
Risedronate sodium
Risedronate sodium

Information

Therapeutic Area: Musculo-skeletal systemEU DMF availableUS DMF no. 20384 availableJapanese DMF availableCEP available Indication: Risedronate sodium is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism.
Main Categories
APIs (Active Pharmaceutical Ingredients)
Available In
OceaniaNorth America (USA, Canada)Middle East Region (e.g. UAE)Central America (e.g. Mexico)East Asia (e.g. China, Japan, Korea)Europe - EU countriesEurope - non EU (e.g. UK, Russia, ex-CIS countries)South America (e.g. Brazil, Colombia)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)
All Categories
APIs (Active Pharmaceutical Ingredients)
Supplied From
Poland
Polpharma GroupPolpharma API European CDMO partner and API manufacturer since 1951. Poland-based CDMO and API producer, delivering products to pharmaceutical companies worldwide. Aiming at the continuous development of Polpharma and caring for the future of patients, business partners and our employees, we are launching a specialized facility for the R&D and Production of HPAPI with an OEL value of 10 ng/m3 (OEB 6). The HP API investment includes separate process laboratories (PDL), analytical laboratories (ADL) with the possibility of performing QC analyses, and a GMP kilo-lab production line with volume up to 1.5 kg with potential volume increase. Our new HPAPI multipurpose facility is a suite for a few classes of products: - compounds essential for creating ADCs - HPAPIs - any other API with higher potencie This outstanding investment makes Polpharma and Poland a strong pillar of the global pharmaceutical industry in the coming decades.

Log in

See all the content and easy-to-use features by logging in or registering!